Genomic of CONgenital Sideroblastic Anemias

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorCentre Hospitalier Universitaire, Amiens

About this trial

Congenital sideroblastic anemias (CSA) are a group of rare disorders characterized by abnormal iron utilization during erythropoiesis, leading to mitochondrial iron overload, the formation of ring sideroblasts, and ineffective erythropoiesis resulting in anemia. Ring sideroblasts are erythroid precursors that contain non-heme iron deposits in their mitochondria, forming a distinctive ring-like pattern around the nucleus. Mitochondria are double membrane organelle provide a large amount of energy for cellular activities, by the process of oxidative phosphorylation (OXPHOS). The role of mitochondria has been well described in erythropoiesis. CSA exhibits clinical heterogeneity, affecting only the erythroid system in some cases, while in others presenting as part of broader syndromic conditions. Their molecular basis remains imperfectly known, although the development of next- generation sequencing technology brought tremendous advances in the understanding of their genetic features. More than 20 genes have been identified as causative of CSA, with all modes of inheritance observed: X-linked recessive, autosomal dominant, autosomal recessive, pseudo- dominant, and mitochondrial. These genes are typically involved in one of four key mitochondrial pathways: i) Heme biosynthesis (e.g., ALAS2, SLC25A38); ii) Iron-sulfur cluster biosynthesis and transport (e.g., GLRX5, HSPA9, HSCB); iii) tRNA synthesis and maturation (e.g., PUS1, YARS2, LARS2, IARS2, SARS2, MARS1, TRNT1); iv) Mitochondrial respiratory chain synthesis (e.g., NDUFB11).

However, in nearly 30% of cases within the French CSA cohort, the underlying genetic cause remains unknown. In these patients with molecularly unexplained whole genome or exome sequencing approaches focusing on genes involved in mitochondrial function and iron metabolism identified several possibly pathogenic variants in CSA patients. These genes were not clearly described as playing a role in erythropoiesis or heme or iron metabolism. We hope to confirm their role in CSA. However, in nearly 30% of cases within the French CSA cohort , the underlying genetic cause remains unknown. The investigators hope to confirm the role in CSA of gene identified with exome sequencing approaches.

Eligibility criteria

This trial accepts healthy volunteers

Qualifiers

Patient with unexplained congenital sideroblastic anemia on the molecular side with the gene panels used routinely

Patients already identified by exome sequencing approach carrying bi-allelic variants of candidate genes of the mitochondrial respiratory pathway.

Patients meeting the same criteria who will be identified prospectively over the next 12 months

Disqualifiers

NA

Trial design

Design model

Parallel

Treatments tested in this trial

  • blood redrawal

    Biological/Vaccine

    Peripheral blood mononuclear cells collected in EDTA (7 mL) and ACD tube (7 mL) during a routine sample collection for patients

Treatment groups

20 Participants
are divided into 2 treatment groups
Group A: Congenital sideroblastic anemiaExperimental treatment 1 intervention
Group B: Patients without Congenital sideroblastic anemiaActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

Identification of genetic variants in Congenital sideroblastic anemias

Variants potentially altering the splicing site

Time frame
1 year
2

Identification of nonsense and missense genetic variants in Congenital sideroblastic anemias

Nonsense and missense variants: study of protein expression or protein size by Western Blot or protein-protein interactions in blood mononuclear cells

Time frame
1 year

Secondary outcomes

1

level of mitochondrial membrane potential

Measurement of the level of mitochondrial membrane potential (TMRM in flow cytometry)

Time frame
1 year
2

Measurement of mitochondrial Ros production

Measurement of mitochondrial Ros production (Mitosox in flow cytometry)

Time frame
1 year
3

Measurement of mitochondrial mass

Measurement of mitochondrial mass (MitoTracker in flow cytometry)

Time frame
1 year
4

Measurement of erythroid differentiation

Measurement of erythroid differentiation

Time frame
1 year

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.